The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot

Completed · Not applicable · Has a placebo group

Conditions studied: Arrhythmia

In brief

The purpose of this study is to learn if combination therapy with amiodarone and ranolazine (an approved drug for chest pain) can help prevent arrhythmias.

Key facts

Study ID

NCT01480336

Run by

Hartford Hospital

People needed

19

Starts

2011-02-01

Expected to finish

2013-01-01

Last updated by the study team

2013-03-19

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with an ICD who were on a stable dose of amiodarone for the past 60 days

You may not qualify if…

• Patients with a life expectancy of less than 6 months
• Patients with moderate or severe hepatic impairment (Child-Pugh Classes B or C) or requiring hemodialysis.
• Pregnancy or lactation.
• Treatment with potent CYP3A inhibitors, including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, indinavir, and saquinavir
• Treatment with CYP3A inducers, including rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John's wort.

Where it is running

• Hartford Hospital — Hartford, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.